Chymotrypsin Therapy
Report summarizes chymotrypsin therapy study findings from Proteolix, Inc.
Published in Health Business Week, January 8th, 2010
According to a study from the United States, "Carfilzomib is a proteasome inhibitor in clinical development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome (c20S) and the immunoproteasome (i20S). To investigate the impact of inhibiting the CT-L activity with carfilzomib, we set out to quantitate the levels of CT-L subunits beta 5 from the c20S and LMP7 from the i20S in normal and malignant hematopoietic cells."
"We found that the i20S is a major form of the proteasome expressed in cells of hematopoietic origin, including multiple myeloma (MM) CD138(+) tumor cells. Although specific inhibition of either LMP7 or beta 5...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2010-01-08)
More Articles from Health Business Week
- 20/20 Companies
20/20 Companies Benefits Children's Hospital Through Holiday Toy Drive - 3D
3D DIAGNOSTIC IMAGING PLC "3D" or "the Company" PLUS ticker 3DDP 510k Clearance for CarieScan PROtm : Approval number: K090598 - 3M
3M Introduces Physician Dictation on BlackBerry and Windows Mobile Smartphones - AARP Idaho
AARP Idaho Applauds Senate for Moving Health Care Reform Forward - AARP Idaho
AARP Urges Idaho Senators Not to be the Grinches That Stole Health Care Reform - AARP Idaho
Health Care Reform Moves One Step Closer to Bringing Relief to Idaho Families - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
